Bruceoside ACAS# 63306-30-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 63306-30-9 | SDF | Download SDF |
| PubChem ID | 441789 | Appearance | Powder |
| Formula | C32H42O16 | M.Wt | 682.7 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | methyl (1R,2S,3R,6R,8S,9S,13S,14R,15R,16S,17S)-15,16-dihydroxy-9,13-dimethyl-3-(3-methylbut-2-enoyloxy)-4,10-dioxo-11-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-11-ene-17-carboxylate | ||
| SMILES | CC1C2CC3C45COC(C4C(C(=O)O3)OC(=O)C=C(C)C)(C(C(C5C2(C=C(C1=O)OC6C(C(C(C(O6)CO)O)O)O)C)O)O)C(=O)OC | ||
| Standard InChIKey | AKSGLPBROCFVSE-TUHDNREHSA-N | ||
| Standard InChI | InChI=1S/C32H42O16/c1-11(2)6-17(34)48-23-25-31-10-44-32(25,29(42)43-5)26(40)22(39)24(31)30(4)8-14(18(35)12(3)13(30)7-16(31)47-27(23)41)45-28-21(38)20(37)19(36)15(9-33)46-28/h6,8,12-13,15-16,19-26,28,33,36-40H,7,9-10H2,1-5H3/t12-,13-,15+,16+,19+,20-,21+,22+,23+,24+,25+,26-,28+,30-,31+,32-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Bruceoside A could be transformed into the potent anticancer component brusatol in vivo, rather than its direct deglycosylated metabolite bruceosin. It significantly inhibited P-388 lymphocytic leukemic cell RNA and protein synthesis in tissue culture. |
| Targets | RNA synthesis |
| In vitro | Antitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells.[Pubmed: 458610 ]J Pharm Sci. 1979 Jul;68(7):883-7.
The quassinoids bruceantin, brucein D, brucein E, Bruceoside A, and brusatol significantly inhibited P-388 lymphocytic leukemic cell RNA and protein synthesis in tissue culture. However, DNA synthesis inhibition seemed to correlate more directly with the anti-neoplastic activity of these compounds in the in vivo P-338 survival system. |
| In vivo | Pharmacokinetic study on bruceoside A revealed the potential role of quassinoid glycosides for the anticancer properties of Fructus Bruceae.[Pubmed: 30947127 ]J Pharm Biomed Anal. 2019 Jun 5;170:264-272.Bruceoside A, an abundant quassinoid glycoside in Fructus Bruceae, was chosen for the pharmacokinetic study. It is the first case report on the pharmacokinetic study of quassinoid glycosides so far.
|
| Structure Identification | Planta Med. 2002 Aug;68(8):730-3.Bioactive constituents of the seeds of Brucea javanica.[Pubmed: 12221597 ]
|
Bruceoside A Dilution Calculator
Bruceoside A Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.4648 mL | 7.3239 mL | 14.6477 mL | 29.2954 mL | 36.6193 mL |
| 5 mM | 0.293 mL | 1.4648 mL | 2.9295 mL | 5.8591 mL | 7.3239 mL |
| 10 mM | 0.1465 mL | 0.7324 mL | 1.4648 mL | 2.9295 mL | 3.6619 mL |
| 50 mM | 0.0293 mL | 0.1465 mL | 0.293 mL | 0.5859 mL | 0.7324 mL |
| 100 mM | 0.0146 mL | 0.0732 mL | 0.1465 mL | 0.293 mL | 0.3662 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Veratrosine
Catalog No.:BCN8637
CAS No.:475-00-3
- (Z)-Aldosecologanin
Catalog No.:BCN8636
CAS No.:82474-97-3
- Dihydrolicoisoflavone
Catalog No.:BCN8635
CAS No.:164163-92-2
- Kushenol S
Catalog No.:BCN8634
CAS No.:254886-72-1
- 2,3,4,5-Tetracaffeoyl-D-glucaric acid
Catalog No.:BCN8633
CAS No.:1419478-52-6
- Saikosaponin E
Catalog No.:BCN8632
CAS No.:64340-44-9
- 2-Amino-N-(2-bromophenyl)benzamide
Catalog No.:BCN8631
CAS No.:34489-85-5
- Glyasperin F
Catalog No.:BCN8630
CAS No.:145382-61-2
- Bacopaside V
Catalog No.:BCN8629
CAS No.:620592-16-7
- Saikosaponin G
Catalog No.:BCN8628
CAS No.:99365-19-2
- 17-Hydroxyisolathyrol
Catalog No.:BCN8627
CAS No.:93551-00-9
- Leonloside D
Catalog No.:BCN8626
CAS No.:20830-84-6
- Glabrone
Catalog No.:BCN8639
CAS No.:60008-02-8
- Hypaconine
Catalog No.:BCN8640
CAS No.:63238-68-6
- Lancifodilactone C
Catalog No.:BCN8641
CAS No.:663176-26-9
- Myrrhone
Catalog No.:BCN8642
CAS No.:183551-83-9
- Caesappanin C
Catalog No.:BCN8643
CAS No.:1913319-59-1
- (1S,2S)-threo-Honokitriol
Catalog No.:BCN8644
CAS No.:1099687-80-5
- 1''-O-beta-D-glucopyranosylformoside
Catalog No.:BCN8645
CAS No.:148245-77-6
- 14,15beta-Dihydroxyklaineanone
Catalog No.:BCN8646
CAS No.:137359-82-1
- Nephthenol
Catalog No.:BCN8647
CAS No.:53915-41-6
- Bryodulcosigenin
Catalog No.:BCN8648
CAS No.:4965-97-3
- Euphorbia factor L7b
Catalog No.:BCN8649
CAS No.:93550-95-9
- Nortracheloside
Catalog No.:BCN8650
CAS No.:33464-78-7
Pharmacokinetic study on bruceoside A revealed the potential role of quassinoid glycosides for the anticancer properties of Fructus Bruceae.[Pubmed:30947127]
J Pharm Biomed Anal. 2019 Mar 23;170:264-272.
Bruceoside A, an abundant quassinoid glycoside in Fructus Bruceae, was chosen for the pharmacokinetic study. It is the first case report on the pharmacokinetic study of quassinoid glycosides so far. A sensitive, accurate, and repeatable UHPLC-MS/MS method was developed for the determination of Bruceoside A and its major metabolite. The results showed Bruceoside A could be transformed into the potent anticancer component brusatol in vivo, rather than its direct deglycosylated metabolite bruceosin. And the intestinal bacteria were proposed to take a potential role during such transformation. Based on the present study, it could be concluded that the quassinoid glycosides possessing weak activities in vitro could do contribution to the anticancer properties of Fructus Bruceae in vivo via transforming into more active metabolites.
Bioactive constituents of the seeds of Brucea javanica.[Pubmed:12221597]
Planta Med. 2002 Aug;68(8):730-3.
A new quassinoid, yadanziolide S (1), was isolated from the seeds of the traditional Chinese medicinal herb, Brucea javanica, along with ten known compounds, flazin, bruceine D, yadanziolide B, Bruceoside A, yadanziolide S, yadanzigan, glycerol 1,3-bisoleate, azelaic acid, (+/-)-8-hydroxyhexadecanoic acid, and vanillin. Compound 1 is the first quassinoid to have been isolated from B. javanica without a methyleneoxy bridge between C-8 and C-13, and its structure was determined using spectroscopic methods, and confirmed by single-crystal X-ray diffraction. All isolates were evaluated for their potential to induce human promyelocytic leukemia (HL-60) cell differentiation, and to inhibit cyclooxygenase-1 (COX-1), -2 (COX-2), and 7,12-dimethylbenz[a]anthracene (DMBA)-induced lesions in a mouse mammary organ culture model.
[Studies on pharmacologically active principles from Indonesian crude drugs. III. Toxic components from Brucea javanica (L.) Merr].[Pubmed:2082013]
Yakugaku Zasshi. 1990 Nov;110(11):834-8.
During our screening of pharmacologically active principles from Indonesian medicinal plants by a hypothermic effect the methanol-extract of Brucea javanica (L.) Merr. has been found to exhibit a lethal toxicity to mice. The toxic components were isolated and identified with Bruceoside A and B and yadanzioside F. Correction of 13C-nuclear magnetic resonance assignment was also mentioned.
Antitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells.[Pubmed:458610]
J Pharm Sci. 1979 Jul;68(7):883-7.
The quassinoids bruceantin, brucein D, brucein E, Bruceoside A, and brusatol significantly inhibited P-388 lymphocytic leukemic cell RNA and protein synthesis in tissue culture. However, DNA synthesis inhibition seemed to correlate more directly with the anti-neoplastic activity of these compounds in the in vivo P-338 survival system. In vitro, brusatol and Bruceoside A marginally inhibited 10-day P-388 lymphocytic leukemia DNA polymerase, RNA polymerase, thymidylate synthetase, dihydrofolate reductase, phosphoribosyl pyrophosphate aminotransferase, and cathepsin protease activities. In vivo studies demonstrated similar inhibition and elevated cyclic AMP levels, correlating positively with the antineoplastic activity of individual compounds. Purine synthesis was inhibited drastically by brusatol in vivo, and one key inhibition site in purine synthesis was at phosphoribosyl pyrophosphate aminotransferase, the regulatory enzyme. Histone phosphorylation and ribonucleotide reductase activity also were inhibited marginally by brusatol.
Antitumor agents. XXXV: Effects of brusatol, bruceoside A, and bruceantin on P-388 lymphocytic leukemia cell respiration.[Pubmed:222889]
J Pharm Sci. 1979 Jul;68(7):887-90.
Brusatol, a quassinoid with potent antineoplastic activity against P-388 lymphocytic leukemia cell proliferation, significantly inhibited P-388 cell hexokinase, phosphofructokinase, malic dehydrogenase, and succinic dehydrogenase. Mitochondrial oxidative phosphorylation, basal, and adenosine diphosphate-stimulated respiration, utilizing succinate and alpha-ketoglutarate as the substrate, was suppressed significantly by in vivo treatment with brusatol. However, brusatol treatment had no effect on liver oxidative phosphorylation. Brusatol greatly increased P-388 cyclic AMP levels but had no effect on liver cyclic nucleotides. Similar inhibitory effects on P-388 cell oxidative phosphorylation were found in vitro with brusatol, Bruceoside A, and bruceantin. Brusatol had no effect on adenosine triphosphatase activity or on uncoupling of oxidative phosphorylation. Rather, brusatol appeared to increase the concentration of reduced mitochondrial electron-transport cofactors, thereby blocking aerobic respiration. A proposed mechanism of action is discussed.
